

NOTICE

SHORTER NOTICE is hereby given that the **14th Annual General Meeting** of Biodeal Pharmaceuticals Private Limited (CIN: U00304HP2005PTC029451) will be held on **Monday, the 30th day of September, 2019** at 11:00 am at the Registered office of the Company to transact the following business:

ORDINARY BUSINESS

1) To receive, consider and adopt the Audited Balance Sheet as at 31st March, 2019 and the Statement of Profit and Loss for the year ended on that date, together with the Auditors' and Directors' Report thereon.

2) To Consider the Re-appointment of the Current Auditors M/s Joshi Vishal & Associates, Chartered Accountants, Chandigarh (Firm Registration No 016437N), as the Statutory Auditors of the Company and to fix their remuneration and to pass the following resolution as an Ordinary Resolution:

“RESOLVED THAT pursuant to the provisions of Section 139 and all other applicable provision of the Companies Act 2013, read with Rule 3(7) of the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force), **M/s Joshi Vishal & Associates, Chartered Accountants, Chandigarh (Firm Registration No-016437N)**, be hereby appointed as the Statutory auditor of the Company for 5 consecutive years to hold the office from conclusion of this meeting until the conclusion of Eighteenth Annual General Meeting of the Company on such remuneration as may be decided by the Board of Directors in Consultation with the Statutory Auditors of the Company.

**By Order of the Board of Directors
BIODEAL PHARMACEUTICALS PRIVATE LIMITED**

For Biodeal Pharmaceuticals Pvt. Ltd.



Director

**GUNJAN KUMAR
DIRECTOR**

DIN: 05203788

**POCKET A-8 HOUSE NO 102
1ST FLOOR KALKAJI EXTENSION
NEW DELHI, 110019**

**PLACE: NALAGARH
DATE: 10.09.2019**



Corp. Off.: DLF Tower B, 7th Floor, 710-712,
Jasola District Centre, New Delhi-110025, INDIA
Tel +011-46106868/69
CIN No. U00304HP2005PTC029451
E-mail: info@biodealpharma.com
www.biodealpharma.com



NOTES:

- 1. A MEMBER ENTITLED TO ATTEND AND VOTE IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE INSTEAD OF HIMSELF AND THE PROXY NEED NOT BE A MEMBER.**
- 2. THE INSTRUMENT APPOINTING PROXY MUST BE LODGED AT THE REGISTERED OFFICE OF THE COMPANY ATLEAST 48 HOURS PRIOR THE TIME OF THE MEETING.**
- 3. MEMBERS/ PROXIES SHOULD BRING THE ATTENDANCE FORMS DULY FILLED IN FOR ATTENDING THE MEETING.**
- 4. MEMBERS ARE REQUESTED TO KINDLY BRING THEIR COPIES OF ANNUAL REPORT TO THE MEETING.**
- 5. THE MEETING IS BEING CONVENED AT A SHORTER NOTICE, AFTER OBTAINING THE CONSENT, IN WRITING, OF MORE THAN 95% OF THE MEMBERS OF THE COMPANY, PURSUANT TO THE PROVISIONS OF SECTION 101 OF THE ACT.**
- 6. ROUTE MAP TO THE VENUE OF ANNUAL GENERAL MEETING OF THE COMPANY IS GIVEN AS ANNEXURE-A TO THIS NOTICE.**

For Biodeal Pharmaceuticals Pvt. Ltd.

Gunjan Kumar

Director



Corp. Off.: DLF Tower B, 7th Floor, 710-712,
Jasola District Centre, New Delhi-110025, INDIA
Tel +011-46106868/69
CIN No. U00304HP2005PTC029451
E-mail: info@biodealpharma.com
www.biodealpharma.com



ATTENDANCE SLIP

I certify that I am a member/ proxy for the member of the Company.

I hereby record my presence at the 14th Annual General Meeting of the Company being held on **Monday, the 30TH day of September, 2019** at 11:00 am at the Registered office of the Company

.....

Full Name of the Member

(IN BLOCK LETTERS)

Folio No/ Client-ID.....

No. of Shares held.....

.....

Signature

.....

Full Name of the Proxy

(IN BLOCK LETTERS)

.....

Signature

NOTE: Members attending the meeting in person or by proxy are requested to complete the attendance slip and hand it over at the entrance of the meeting hall.

For Biodeal Pharmaceuticals Pvt. Ltd.

Director



Corp. Off.: DLF Tower B, 7th Floor, 710-712,
Jasola District Centre, New Delhi-110025, INDIA
Tel +011-46106868/69
CIN No. U00304HP2005PTC029451
E-mail: info@biodealpharma.com
www.biodealpharma.com



**PROXY FORM
(Form No. MGT-11)**

**[Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies
(Management and Administration) Rules, 2014]**

Name of the Member(s): _____
Registered Address: _____

Email Id: _____
Folio No./ DP Id and Client ID: _____

I/we being the member(s) of the above named Company hereby appoint

1. Name: _____ Email Id: _____
Address: _____
_____ Signature:

or failing him/her

2. Name: _____ Email Id: _____
Address: _____
_____ Signature:

or failing him/her

3. Name: _____ Email Id: _____
Address: _____
_____ Signature:

as my/our proxy to attend and vote, in case of a poll, for me/us and on my/our behalf at the **14th Annual General Meeting** of the Company to be held on **Monday, the 30th day of September, 2019** at 11:00 am at the Registered office of the Company and at any adjournment thereof in respect of such resolutions as are indicated below:

For Biodeal Pharmaceuticals Pvt. Ltd.

Director



Corp. Off.: DLF Tower B, 7th Floor, 710-712,
Jasola District Centre, New Delhi-110025, INDIA
Tel +011-46106868/69
CIN No. U00304HP2005PTC029451
E-mail: info@biodealpharma.com
www.biodealpharma.com

Signed this..... day of.....2019

Resolution No.	Description	Re. 1/-	For*	Against*
		Revenue Stamp		
1.	To consider and adopt audited financial statements, reports of the Auditors and Directors thereon			
2.	Re-appointment of the Current Auditors M/s Joshi Vishal & Associates, Chartered Accountants, Chandigarh (Firm Registration No 016437N), as the Statutory Auditors of the Company and to fix their remuneration			

Signature.....


NOTES:

1. *Please put a 'X' in the appropriate column against the resolutions indicated in the Box. If you leave the 'For' or 'Against' column blank against any or all the resolutions, your Proxy will be entitled to vote in the manner as he/she thinks appropriate.
2. This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the Meeting.
3. A Proxy need not be a member of the Company. Pursuant to the provisions of Section 105 of the Companies Act, 2013, a person can act as proxy on behalf of not more than fifty members and holding in aggregate not more than ten percent of the total Share Capital of the Company. Members holding more than ten percent of the total Share Capital of the Company may appoint a single person as proxy, who shall not act as proxy for any other member.
4. Appointing a proxy does not prevent a member from attending the meeting in person if he so wishes.

For Biodeal Pharmaceuticals Pvt. Ltd.

Gunjan Kumar

Director



Boards' Report

Dear Members,

BIODEAL PHARMACEUTICALS PRIVATE LIMITED
VILLAGE SAINI MAJRA, NALAGARH-ROPAR ROAD,
TEH, NALAGARH, DISTT. SOLAN (HP)

Your Directors have pleasure in presenting their 14th Annual Report on the business and operations of the Company and the accounts for the Financial Year ended **March 31, 2019**.

1. Financial summary or highlights/Performance of the Company (Standalone)

FINANCIAL RESULTS	CURRENT YEAR (INR)	PREVIOUS YEAR (INR)
INCOME	46,91,97,164	34,98,67,614
EXPENDITURE	43,90,57,466	33,05,83,876
PROFIT (LOSS) BEFORE TAX	3,01,39,698	1,92,83,739
PROFIT (LOSS) AFTER TAX	2,17,54,835	1,43,18,175

2. Dividend

Your directors do not recommend any dividend for the F.Y. 2018-19.

3. Reserves


S.NO	PARTICULARS	2018-2019 (Amount in Rs.)	2017-18 (Amount in Rs.)
A	GENERAL RESERVE		
	As Per Last Balance Sheet	1,10,19,833	(32,98,342)
	Add/Less: Deferred Tax Liability/Asset	0.00	0.00
	Less Last year tax	(1070)	0
	Add: Transferred from Profit & Loss A/c	2,17,54,835.00	1,43,18,175.00

For Biodeal Pharmaceuticals Pvt. Ltd.

Arun Kumar
Director

For Biodeal Pharmaceuticals Pvt. Ltd.

Shrigh
Director



	BALANCE AT THE END OF THE YEAR (A)	3,27,73,598	1,10,19,833.00
B	PROFIT AND LOSS A/c		
	As Per Last Balance Sheet	0	0
	Add: Profit (Loss) for the year	2,17,54,835	1,43,18,175.00
	Less: Appropriation transferred to General Reserve	2,17,54,835	1,43,18,175.00
	BALANCE AT THE END OF THE YEAR (B)	0	0
Total (A+B)		3,27,73,598	1,10,19,833.00

4. Brief description of the Company's working during the year/State of Company's affair

During the year the income of the Company was under:

PARTICULARS	CURRENT YEAR	PREVIOUS YEAR
Revenue From The Operation	46,69,71,243	34,85,63,080
Other Income	22,25,921	13,04,534
TOTAL	46,91,97,164	34,98,67,614

STATE OF COMPANY'S AFFAIR

PARTICULARS	CURRENT YEAR	PREVIOUS YEAR
Shareholders fund:		
A)Share Capital	25,00,00,000	25,00,00,000
B)Reserves And Surplus	3,27,73,598	1,10,19,833
Non-current liabilities	13,82,83,296	127453903

For Biodeal Pharmaceuticals Pvt. Ltd.
Gunjan Kaur
Director

For Biodeal Pharmaceuticals Pvt. Ltd.
Shruti
Director



Corp. Off.: DLF Tower B, 7th Floor, 710-712,
Jasola District Centre, New Delhi-110025, INDIA
Tel +011-46106888/89
CIN No. U00304HP2005PTC029451
E-mail: info@biodealpharma.com
www.biodealpharma.com



Current liabilities	24,91,95,264	18,53,28,495
TOTAL	67,02,52,158	57,38,02,231
Noncurrent Assets	34,64,05,582	360401043
Current Assets	32,38,46,576	21,34,01,188
TOTAL	67,02,52,158	57,38,02,231

5. SHARE CAPITAL

The Authorized Share Capital of the Company is Rs. 25,00,00,000/- (Rupees Twenty Five Crores only) divided into 25000000 Equity Shares of Rs. 10/- (Rupees Ten) each.

The paid-up Share Capital as on March 31, 2019 is Rs. 25,00,00,000/- (Rupees Twenty Five Crores only) divided into 25000000 Equity Shares of Rs. 10/- (Rupees Ten) each.

During the year under review, the Company has not issued any shares or any convertible instruments.

6. DEPOSITS

The Company has not accepted deposit from the public within the ambit of Section 73 of the Companies Act, 2013 and The Companies (Acceptance of Deposits) Rules, 2014.

7. MATERIAL CHANGES BETWEEN THE DATE OF THE BOARD REPORT AND END OF FINANCIAL YEAR

There have been no material changes and commitments affecting the financial position of the Company which have occurred between the end of the financial year of the Company to which the financial statements relate and the date of the report.

8. DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS IMPACTING THE GOING CONCERN STATUS AND COMPANY'S OPERATIONS IN FUTURE:

No such orders have been passed by any of the Regulators/Courts/Tribunals impacting the going concern status and company's operations in future for the F.Y. 2018-19.

9. DETAILS OF SUBSIDIARY/JOINT VENTURES/ ASSOCIATE COMPANIES

During the F.Y. 2018-19, the Company does not have any subsidiary/ joint venture/ associate companies.

For Biodeal Pharmaceuticals Pvt. Ltd.

Geetanjali Kaur
Director

For Biodeal Pharmaceuticals Pvt. Ltd.

Shingh
Director



10. CHANGE IN THE NATURE OF BUSINESS

There is no change in the nature of the business of the Company during the F.Y. 2018-19.

11. EXTRACT OF ANNUAL RETURN

The Extract of Annual Return as required under section 92(3) of the Companies Act, 2013 in Form MGT-9 is annexed as **Annexure -1** for your kind perusal and information.

12. MEETINGS OF THE BOARD OF DIRECTORS

The Board met 5 times during the F.Y. 2018-19 and the intervening gap between any two meetings was within the time prescribed under the Companies Act, 2013.

Presence of Directors					
	27 th April, 2018	23 rd July 2018	4 th September, 2018	3 rd December,2018	14 th March,2019
GUNJAN KUMAR	✓		✓	✓	✓
SUBODH PRASAD SINGH	✓		✓	✓	✓

13. CHANGES IN DIRECTORS AND KEY MANAGERIAL PERSONNEL:

There is no change in the Board of Directors of the Company during the Financial Year 2018-19.

14. RECEIPT OF ANY COMMISSION BY MD/WTD FROM THE COMPANY OR FOR THE RECEIPT OF COMMISSION/REMUNERATION FROM ITS HOLDING OR SUBSIDIARY

Nil

15. LOANS, GUARANTEES AND INVESTMENTS

The Company has no Loans, Guarantee given and Investments made under section 186 of the Companies Act, 2013 for the F.Y. 2018-19.

For Biodeal Pharmaceuticals Pvt. Ltd.
Gunjan Kumar
Director

For Biodeal Pharmaceuticals Pvt. L
Shingh
Direc



16. STATUTORY AUDITORS

Joshi Vishal & Associates Chartered Accountants, Chandigarh were re-appointed as statutory auditor of the Company, to hold office till the AGM to be held for the Financial Year 2023-2024.

17. AUDITORS' REPORT

There are no qualifications or adverse remarks in the Auditors' Report which require any clarification/ explanation. The Notes on financial statements are self-explanatory, and needs no further explanation.

The Auditors' Report for the F.Y. 2018-19 is annexed herewith for your kind perusal and information.

18. SECRETARIAL AUDIT REPORT

Since the Company is a private limited company therefore section 204 of the Companies Act, 2013 is not applicable on the Company.

19. PARTICULARS OF EMPLOYEES AND RELATED DISCLOSURES:

There is no employee who is drawing remuneration exceeding the provision of Section 197 read with rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 during the financial year.

20. DECLARATION BY INDEPENDENT DIRECTOR:

Since the company is a private limited company therefore declaration by Independent Director under section 149(7) of the Companies Act, 2013 is not applicable on the Company.

21. CORPORATE SOCIAL RESPONSIBILITY (CSR) POLICY:

Since the Net Worth of the Company is less than Rs. 500 Crore, Turnover of the Company is less than Rs. 1,000 Crore and the Net Profit of the Company is less than Rs. 5.00 Crore therefore section 135 of the Companies Act, 2013 is not applicable.

22. DIRECTORS RESPONSIBILITY STATEMENT

Pursuant to Section 134(5) of the Companies Act, 2013 the Board of Directors of the Company confirms that-

(a)	In the preparation of the annual accounts for the F.Y. 2018-19, the applicable accounting standards have been followed along with proper explanation relating to material departures;
(b)	The directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the loss of the company for that period;

For Biodeal Pharmaceuticals Pvt. Ltd.


Arun Kumar

Director

For Biodeal Pharmaceuticals Pvt. Ltd.

Shingh

Director



(c)	The directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
(d)	The directors have prepared the annual accounts on a going concern basis; and
(e)	The directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

23. DISCLOSURE UNDER SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

Your directors' further state that during the F.Y. 2018-19 under review, there were no cases filed pursuant to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

24. STATEMENT INDICATING THE MANNER IN WHICH FORMAL ANNUAL EVALUATION HAS BEEN MADE BY THE BOARD OF ITS OWN PERFORMANCE, ITS DIRECTORS, AND THAT OF ITS COMMITTEES:

Since the company is a private limited company therefore section 134(3)(p) is not applicable.

25. VIGIL MECHANISM / WHISTLE BLOWER POLICY

The Company not being listed Company has no such vigil mechanism policy.

26. RELATED PARTY TRANSACTIONS

In accordance with the provisions of section 188 sub-section (2), every contract or arrangement entered into under sub-section (1) shall be referred to in the Board's report to the shareholders along with the justification for entering into such contract or arrangement.


Also, the company has entered into any such contract. Or arrangement referred to in sub-section (1) of section 188 of the Companies Act, 2013 annexed as **Annexure A-2**.

For Biodeal Pharmaceuticals Pvt. Ltd.

Shingh
Director

For Biodeal Pharmaceuticals Pvt. Ltd.

Gunjan Kumar
Director



27. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION

The particulars of energy conservation, technology, absorption is not applicable to the Company.

FOREIGN EXCHANGE EARNINGS AND OUTGO

There were foreign currency transactions during the year details of which are mentioned below: -

Particulars	2018-2019
A) Expenditure in foreign currency	583990.54
B) Earning in foreign currency	1332309

28. RISK MANAGEMENT

Risks are events, situations or circumstances which may lead to negative consequences on the Company's businesses. The company has identified major risks and has developed internal process for risk mitigation. These processes shall be subject to review from time to time by your board.

29. INTERNAL FINANCIAL CONTROLS

Not Applicable

30. DISCLOSURE UNDER SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

Your directors' further state that during the F.Y. 2018-19 under review, there were no cases filed pursuant to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

31. COMMUNICATION:

The Ministry of Corporate affairs has taken green initiative in the corporate governance by allowing the service of document through electronic mode, also Department of posts has recently discontinued the postal facility under certificate of posting so members are requested to intimate the email- id enable the company to communicate easily, timely and in a cost effective manner.

For Biodeal Pharmaceuticals Pvt. Ltd.


Shingh
Director

For Biodeal Pharmaceuticals Pvt. Ltd.

Arun Kumar
Director



Corp. Off.: DLF Tower B, 7th Floor, 710-712,
Jasola District Centre, New Delhi-110025, INDIA
Tel +011-46106868/69
CIN No. U00304HP2005PTC029451
E-mail: info@biodealpharma.com
www.biodealpharma.com



32. ACKNOWLEDGEMENT

Your Directors wish to express their grateful appreciation to the continued co-operation received from the Banks, Government Authorities and Shareholders during the F.Y. 2018-19 under review. Your Directors also wish to place on record their deep sense of appreciation for the committed service of the Executives, Staff and Workers of the Company.

By Order of the Board of Directors

BIODEAL PHARMACEUTICALS PRIVATE LIMITED

For Biodeal Pharmaceuticals Pvt. Ltd.

Director

GUNJAN KUMAR
DIRECTOR
DIN No. 05203788
POCKET A-8 HOUSE NO 102
1ST FLOOR KALKAJI EXTENSION
NEW DELHI, 110019


For Biodeal Pharmaceuticals Pvt. Ltd.

Director

SUBODH PRASAD SINGH
DIRECTOR
DIN No. 07148323
FLAT NO 202, BHAGWATI APARTMENT
M.G ROAD, BHAGALPUR,
BIHAR, 812001

PLACE: NALAGARH

DATE: 10.09.2019



Form No. AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)


Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arm's length transactions under third proviso thereto.

1. Details of contracts or arrangements or transactions not at arm's length basis

(a) Name(s) of the related party and nature of relationship	NOT APPLICABLE
(b) Nature of contracts/arrangements/transactions	NOT APPLICABLE
(c) Duration of the contracts / arrangements/transactions	NOT APPLICABLE
(d) Salient terms of the contracts or arrangements or transactions including the value, if any	NOT APPLICABLE
(e) Justification for entering into such contracts or arrangements or transactions	NOT APPLICABLE
(f) date(s) of approval by the Board	NOT APPLICABLE
(g) Amount paid as advances, if any:	NOT APPLICABLE
(h) Date on which the special resolution was passed in general meeting as required under first proviso to section 188	NOT APPLICABLE

For Biodeal Pharmaceuticals Pvt. Ltd.
Arun Kumar
Director

For Biodeal Pharmaceuticals Pvt. Ltd.
Shingh
Director




2. Details of material contracts or arrangement or transactions at arm's length basis

S. NO	Name(s) of the related party and nature of relationship	Nature of contracts/arrangements/transactions	Duration of the contracts/arrangements/transactions	Salient terms of the contracts or arrangements or transactions including the value, if any	Amount For the Year ended March 31, 2019	Date(s) of approval by the Board, if any:	Amount paid as advanced if any:
1.	Atlantas worldwide Pvt Ltd	Services	AS PER COMPANY POLICIES	Clearing Expenses	6095881	15.04.2017	NIL
2.	Lobster Overseas	Sale	AS PER COMPANY POLICIES	Supply of Material	11342260	15.04.2017	NIL

By Order of the Board of Directors

BIODEAL PHARMACEUTICALS PRIVATE LIMITED

For Biodeal Pharmaceuticals Pvt. Ltd.



GUNJAN KUMAR
DIRECTOR
DIN No. 05203788
POCKET A-8 HOUSE NO 102
1ST FLOOR KALKAJI EXTENSION
NEW DELHI, 110019

For Biodeal Pharmaceuticals Pvt. Ltd.



Director

SUBODH SINGH PRASAD
DIRECTOR
DIN No. 07148323
FLAT NO 202, BHAGWATI APARTMENT
M.G ROAD, BHAGALPUR,
BIHAR, 812001

PLACE: NALAGARH

DATE: 10.09.2019



Annexure-1

Form No. MGT-9

Extract of Annual Return as on the Financial Year ended on 31.03.2019

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:	
CIN:-	U00304HP2005PTC029451
Registration Date	30.12.2005
Name of the Company	BIODEAL PHARMACEUTICALS PRIVATE LIMITED
Category / Sub-Category of the Company	COMPANY LIMITED BY SHARES
Address of the Registered office and contact details	Village Saini Majra, Nalagarh-Ropar road, Teh, Nalagarh, Distt. Solan (hp)
Whether listed company Yes /	No
Name, Address and Contact details of Registrar and Transfer Agent (RTA)	NA

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

All the business activities contributing 10 % or more of the total turnover of the company shall be stated:-

S. NO.	NAME AND DESCRIPTION OF MAIN PRODUCTS /SERVICES	NIC CODE OF THE PRODUCT/SERVICE	% TO TOTAL TURNOVER OF THECOMPANY
01	MANUFACTURING OF PHARMACEUTICALS	24	100%

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES

S. NO.	NAME AND ADDRESS	CIN/GLN	HOLDING/ SUBSIDIARY/	% OF SHARES	APPLICABLE SECTION
---------------	-------------------------	----------------	-----------------------------	--------------------	---------------------------

For Biodeal Pharmaceuticals Pvt. Ltd.

Arun Kumar

Director

For Biodeal Pharmaceuticals Pvt. Ltd.

Hingh

Director



	OF THE COMPANY		ASSOCIATE	HELD	
-----NIL-----					

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

i) Category-wise Share Holding

Category of Shareholders	No. of Shares held at the beginning of the year[As on 31-March-2018]				No. of Shares held at the end of the year[As on 31-March-2019]				% Change during the year
	Demat	Physical	Total	% of Total Shares	De mat	Physical	Total	% of Total Shares	
A. Promoters									
(1) Indian									
a) Individual/ HUF	NIL	2,50,00,000	2,50,00,000	100.00%	NIL	2,50,00,000	2,50,00,000	100.00%	Nil
b) Central Govt									
c) State Govt(s)									
d) Bodies Corp.									
e) Banks / FI									
f) Any other									
Total shareholding of Promoter (A)	NIL	2,50,00,000	2,50,00,000	100.00%	NIL	2,50,00,000	2,50,00,000	100.00%	Nil
B. Public Shareholding									
1. Institutions									
a) Mutual Funds									
b) Banks / FI									
c) Central Govt									
d) State Govt(s)									
e) Venture Capital Funds									
f) Insurance Companies									
g) FIs									
h) Foreign Venture Capital Funds									
i) Others									

For Biodeal Pharmaceuticals Pvt. Ltd.

Gunjan Kumar

Director

For Biodeal Pharmaceuticals Pvt. Ltd.

Shingh

Director



	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
Sub-total (B)(1):-									
2. Non-Institutions									
a) Bodies Corp.									
i) Indian									
ii) Overseas									
b) Individuals									
i) Individual shareholders holding nominal share capital upto Rs. 1 lakh	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
ii) Individual shareholders holding nominal share capital in excess of Rs 1 lakh	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
c) Others (FOREIGN DIRECTOR)									
Non Resident Indians									
Overseas Corporate Bodies									
Foreign Nationals									
Clearing Members									
Trusts									
Foreign Bodies - D R									
Sub-total (B)(2):-	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
Total Public Shareholding (B)=(B)(1)+ (B)(2)									

For Biodeal Pharmaceuticals Pvt. Ltd.

Deviyan Kumar
Director

For Biodeal Pharmaceuticals Pvt. Ltd.

Shingh
Director



C. Shares held by Custodian for GDRs & ADRs	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
Grand Total (A+B+C)	NIL	2,50,00,000	2,50,00,000	100%	NIL	2,50,00,000	2,50,00,000	100%	NIL

ii) Shareholding of Promoter-

SN	Shareholder's Name	Shareholding at the beginning of the year			Share holding at the end of the year			% change in share holding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	
1	ANURAG KUMAR	24991700	99.97%	NIL	24991700	99.97%	NIL	NIL
2.	SUBODH SINGH PRASAD	8300	0.03%	NIL	8300	0.03%	NIL	NIL

C) Change in Promoters' Shareholding (please specify, if there is no change)

SN	Particulars	Date	Reason	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
				No. of shares	% of total shares	No. of shares	% of total shares
	At the beginning of the year			-	0%	-	0%
	No Changes during the year			-	0%	-	0%
				-	0%	-	0%
				-	0%	-	0%
	At the end of the year			-	0%	-	0%

D) Shareholding Pattern of top ten Shareholders:

(Other than Directors, Promoters and Holders of GDRs and ADRs):

SN	Name	Particulars	Shareholding at the beginning of the year	Cumulative Shareholding during the year
----	------	-------------	-------------------------------------------	-----------------------------------------

For Biodeal Pharmaceuticals Pvt. Ltd.

Anurag Kumar

Director

For Biodeal Pharmaceuticals Pvt. Ltd.

Shingh

Director



		No. of Shares	% of total Shares of the company	No. of Shares	% of total Shares of the company
	NIL	NIL	NIL	NIL	NIL

E) Shareholding of Directors and Key Managerial Personnel:

SN	Shareholding of each Directors and each Key Managerial Personnel	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1	SUBODH SINGH PRASAD	8300	0.03%	8300	0.03%

F) INDEBTEDNESS -Indebtedness of the Company including interest outstanding/accrued but not due for payment:

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
i) Principal Amount	14,59,09,652.00	7,11,50,000.00	--	21,70,59,652.00
ii) Interest due but not paid	--	--		
iii) Interest accrued but not due	--	--		
Total (i+ii+iii)	14,59,09,652.00	7,11,50,000.00	--	21,70,59,652.00
Change in Indebtedness during the financial year				
* Addition	1,50,93,653.00	2,13,49,000.00		3,64,42,653.00
* Reduction			---	
Net Change	1,50,93,653.00	2,13,49,000.00	---	3,64,42,653.00
Indebtedness at the end of the financial year				
i) Principal Amount	16,10,03,305.00	9,24,99,000.00	-----	25,35,02,305.00
ii) Interest due but not paid				
iii) Interest accrued but not due				
Total (i+ii+iii)	16,10,03,305.00	9,24,99,000.00	-----	25,35,02,305.00

For Biodeal Pharmaceuticals Pvt. Ltd.

Geerjan Kumar

Director

For Biodeal Pharmaceuticals Pvt. Ltd.

Shingh

Director



vii.) REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL-

A. Remuneration to Managing Director, Whole-time Directors and/or Manager:

SN.	Particulars of Remuneration	Name of MD/WTD/ Manager				Total Amount
		----	----	----	---	
1	Gross salary					
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	NIL	NIL			NIL
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961					
	(c) Profits in lieu of salary under section 17(3) Income- tax Act, 1961					
2	Stock Option					
3	Sweat Equity					
4	Commission - as % of profit - others, specify...					
5	Others, please specify					
	Total (A)					
	Ceiling as per the Act					

B. Remuneration to other directors

SN.	Particulars of Remuneration	Name of Directors				Total Amount

1	Independent Directors	NIL	NIL	NIL	NIL	NIL
	Fee for attending board committee meetings					
	Commission					
	Others, please specify					
	Total (1)					
2	Other Non-Executive Directors/ Executive Director	Gunjan	NIL	NIL	NIL	NIL

For Biodeal Pharmaceuticals Pvt. Ltd.

Gunjan Kumar

Director

For Biodeal Pharmaceuticals Pvt. Ltd.

Shingh

Direct

	Kumar				
Fee for attending board committee meetings	-	NIL	NIL	NIL	NIL
Commission	-	NIL	NIL	NIL	NIL
Others,(Remuneration)	1,800,000.00	NIL	NIL	NIL	1,800,000.00
Total (2)	1,800,000.00	NIL	NIL	NIL	1,800,000.00
Total (B)=(1+2)	1,800,000.00	NIL	NIL	NIL	1,800,000.00
Total Managerial Remuneration	1,800,000.00	NIL	NIL	NIL	1,800,000.00
Overall Ceiling as per the Act	NIL	NIL	NIL	NIL	NIL

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD

SN	Particulars of Remuneration	Key Managerial Personnel			
		CEO	CS	CFO	Total
1	Gross salary	-----	-----	-----	
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961				
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961				
	(c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961				
2	Stock Option				
3	Sweat Equity				
4	Commission				
	- as % of profit				
	Others specify...				

For Biodeal Pharmaceuticals Pvt. Ltd.

For Biodeal Pharmaceuticals Pvt. Ltd.

Shingh

Director

Arun Kumar

Director



5	Others, please specify				
	Total				

XII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of the Companies Act	Brief Description	Details of Penalty / Punishment/ Compounding fees imposed	Authority [RD / NCLT/ COURT]	Appeal made, if any (give Details)
A. COMPANY					
Penalty			NIL	NIL	NIL
Punishment			NIL	NIL	NIL
Compounding			NIL	NIL	NIL
B. DIRECTORS					
Penalty			NIL	NIL	NIL
Punishment			NIL	NIL	NIL
Compounding			NIL	NIL	NIL
C. OTHER OFFICERS IN DEFAULT					
Penalty			NIL	NIL	NIL
Punishment			NIL	NIL	NIL
Compounding			NIL	NIL	NIL

By Order of the Board of Directors

BIODEAL PHARMACEUTICALS PRIVATE LIMITED For Biodeal Pharmaceuticals Pvt. Ltd.

For Biodeal Pharmaceuticals Pvt. Ltd.

Gunjan Kumar

Director

Shingh

Director

GUNJAN KUMAR
DIRECTOR
DIN No. 05203788
POCKET A-8 HOUSE NO 102
1ST FLOOR KALKAJI EXTENSION
NEW DELHI, 110019

SUBODH PRASAD SINGH
DIRECTOR
DIN No. 07148323
FLAT NO 202, BHAGWATI
APARTMENT M.G ROAD,
BHAGALPUR, BIHAR, 812001

PLACE: NALAGARH
DATE:10.09.2019